These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 19946934)
1. Quetiapine treatment and improved cognitive functioning in borderline personality disorder. Van den Eynde F; De Saedeleer S; Naudts K; Day J; Vogels C; van Heeringen C; Audenaert K Hum Psychopharmacol; 2009 Dec; 24(8):646-9. PubMed ID: 19946934 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. Van den Eynde F; Senturk V; Naudts K; Vogels C; Bernagie K; Thas O; van Heeringen C; Audenaert K J Clin Psychopharmacol; 2008 Apr; 28(2):147-55. PubMed ID: 18344724 [TBL] [Abstract][Full Text] [Related]
3. Quetiapine in patients with borderline personality disorder: an open-label trial. Adityanjee ; Romine A; Brown E; Thuras P; Lee S; Schulz SC Ann Clin Psychiatry; 2008; 20(4):219-26. PubMed ID: 19034754 [TBL] [Abstract][Full Text] [Related]
4. Selective deficit in executive functioning among patients with borderline personality disorder. Haaland VØ; Esperaas L; Landrø NI Psychol Med; 2009 Oct; 39(10):1733-43. PubMed ID: 19243646 [TBL] [Abstract][Full Text] [Related]
5. Effects of quetiapine on cognitive functions in schizophrenic patients: a preliminary single-trial ERP analysis. Zhang Y; Lehmann M; Shobeiry A; Höfer D; Johannes S; Emrich HM; Dietrich DE Pharmacopsychiatry; 2009 Jul; 42(4):129-34. PubMed ID: 19585390 [TBL] [Abstract][Full Text] [Related]
6. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Houthoofd SA; Morrens M; Sabbe BG Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365 [TBL] [Abstract][Full Text] [Related]
7. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174 [TBL] [Abstract][Full Text] [Related]
8. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)]. Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451 [TBL] [Abstract][Full Text] [Related]
9. Quetiapine for the treatment of borderline personality disorder; an open-label study. Perrella C; Carrus D; Costa E; Schifano F Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):158-63. PubMed ID: 17045720 [TBL] [Abstract][Full Text] [Related]
10. [Neuropsychological dysfunctions in personality borderline disorder: detection strategies]. Arza R; Díaz-Marsa M; López-Micó C; de Pablo NF; López-Ibor JJ; Carrasco JL Actas Esp Psiquiatr; 2009; 37(4):185-90. PubMed ID: 19927229 [TBL] [Abstract][Full Text] [Related]
12. Pathological dissociation and neuropsychological functioning in borderline personality disorder. Haaland VØ; Landrø NI Acta Psychiatr Scand; 2009 May; 119(5):383-92. PubMed ID: 19120046 [TBL] [Abstract][Full Text] [Related]
13. A neurocognitive model of borderline personality disorder: effects of childhood sexual abuse and relationship to adult social attachment disturbance. Minzenberg MJ; Poole JH; Vinogradov S Dev Psychopathol; 2008; 20(1):341-68. PubMed ID: 18211741 [TBL] [Abstract][Full Text] [Related]
14. Planning in borderline personality disorder: evidence for distinct subpopulations. Bustamante ML; Villarroel J; Francesetti V; Ríos M; Arcos-Burgos M; Jerez S; Iturra P; Solari A; Silva H World J Biol Psychiatry; 2009; 10(4 Pt 2):512-7. PubMed ID: 19658046 [TBL] [Abstract][Full Text] [Related]